Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunhistochemistry profiling of human endometrial cancer tissue biopsies identified epithelial cells co-expressing ERβ5 and ERα in stage I endometrial adenocarcinomas and post menopausal endometrium.
|
31778358 |
2020 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
There was a weak but statistically significant negative correlation between immunoreactivity of GPR30 and that of ER in cervical AIS and adenocarcinoma lesions (Spearman's correlation, r=-0.324, p=0.017).
|
31483053 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We examined this interplay and response to mTOR inhibition using ERα+ adenocarcinomas from NRL-PRL females in combination with Col1a1<sup>tmJae/+</sup> (mCol1a1) mice, which accumulate collagen-I around growing tumors.
|
29935374 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The most common breast cancer type was adenocarcinomas (59.1%) and half of the breast cancers were hormone sensitive, with estrogen receptor positive status in 10 of 19 tested and progesterone receptor positive status in 5 of 14 tested.
|
30087072 |
2018 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Cervical adenocarcinomas are believed to lose estrogen response on the basis of no expression of a nuclear estrogen receptor such as ERα in clinical pathology.
|
30227306 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Calretinin and cytokeratin 5 were used for reactive mesothelial cells and Wilms tumor 1, thyroid transcription factor 1, CDX2, and estrogen receptor were used to confirm the adenocarcinoma cells.
|
28862203 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
A small subset of pulmonary adenocarcinomas shows immunoreactivity for ER clones 6F11 and 1D5 in FNA samples (18.2% and 9.1%, respectively).
|
29465823 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
E-cadherin correlated with Bak and Bcl-xL in ER-positive adenocarcinomas (p = .002, r = 0.382 and p <.001, r = 0.439, respectively) but not in ER-negative tumors.
|
28937296 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Conditional expression of Ki-Ras<sup>G12V</sup> in the mammary epithelium of transgenic mice induces estrogen receptor alpha (ERα)-positive adenocarcinoma.
|
28745321 |
2017 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Some studies have shown that activation of estrogen and estrogen receptor α or β (ERα/β) promote adenocarcinoma.
|
25692143 |
2015 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The objective was to characterize and associate the receptor reactivities of fibroblastic growth factor (FGF)-2, FGF-7, FGF-8, epidermal growth factor (EGF), α-actin and vimentin in relation to the androgen receptor (AR), α and β estrogen receptors (ERα and ERβ), and prolactin receptor in the prostate of elderly men showing low- and high-grade adenocarcinoma.
|
23362007 |
2013 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Most (90%) of the endometrial adenocarcinomas were positive for vimentin and estrogen receptor, all were negative for HPV, and 97% were negative for carcinoembryonic antigen.
|
23318908 |
2013 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our results indicate that in patients with grade G3 adenocarcinoma, the expression of AT1-R significantly decreased in comparison with G1 patients (p = 0.034), but the level of ERα was the highest in G2 and the lowest in G3.
|
22170435 |
2012 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Such EGFR mutations are frequently found in adenocarcinoma with a strong expression of estrogen receptor (ER) beta, which has been shown to correlate with a favorable prognosis for the patients with EGFR mutations.
|
20615575 |
2011 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, we examined the expression of PGRMC1 and PGRMC2 mRNA by relative quantitative PCR (RelqPCR) and determined whether transcript levels correlate with age, breast cancer staging, estrogen receptor alpha (ERα) status, and other morphometric features routinely used during the pathological examination of breast ductal adenocarcinomas.
|
20655063 |
2011 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
ESR1 gene multiple copies were confirmed in 13/60 (21.6%) breast adenocarcinomas, but high amplification only in 8/13 (62.8%).
|
20458558 |
2011 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
ESR1 gene multiple copies were confirmed in 13/60 (21.6%) breast adenocarcinomas, but high amplification only in 8/13 (62.8%).
|
20458558 |
2011 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Using a script written in R, the diagnostic accuracy of all possible combinations of markers was evaluated and it was shown that a 3 marker panel including vimentin, ER, or PR, and an HPV marker (p16, ProExC, or HPV ISH) is optimal for determining site of origin for usual endometrial and endocervical adenocarcinomas.
|
20534993 |
2010 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Immuno-histochemical examination of the expression of TRPM8 channels in human breast tissues revealed an over-expression of TRPM8 in breast adenocarcinomas, which is correlated with estrogen receptor positive (ER+) status of the tumours.
|
20482834 |
2010 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Human estrogen receptor alpha is highly homologous to estrogen receptor beta and consequently, antibodies used to detect estrogen receptor alpha in breast carcinomas may detect estrogen receptor beta in pulmonary adenocarcinomas.
|
19875957 |
2010 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Estrogen receptor alpha nuclear expression significantly correlated with adenocarcinoma histology, female gender, and history of never smoking (P = 0.0048 to <0.0001).
|
19706809 |
2009 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters.
|
17046193 |
2007 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Coexpression index of estrogen receptor alpha mRNA isoforms in simple, complex hyperplasia without atypia, complex atypical hyperplasia and adenocarcinoma.
|
17561234 |
2007 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Combining 4 genes (CALCA, DAPK, ESR1 and APC) yielded a sensitivity of 89% (with all adenocarcinomas identified), equal to cytomorphology (89%) and high-risk human papilloma virus (Hr-HPV; 90%).
|
16736496 |
2006 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Estrogen receptor (ER) alpha is expressed at low levels in normal epithelia, and its expression is dramatically up-regulated as transformation progresses during mammary hyperplasia and adenocarcinoma development.
|
17108100 |
2006 |